Mutations in GIST
Newly Diagnosed | Glossary | GIST Education | GIST FAQ | Pathology Report Introduction to mutations in GIST The cells in the human body each contain instructions for making the building blocks [...]
11
10, 2012
1
08, 2012
New research supports role for crenolanib
A new study published by Clinical Cancer Research found that crenolanib is a potent inhibitor of imatinib resistant PDGFRA kinases associated with Gastrointestinal Stromal Tumor, including the PDGFRA D842V mutation found in about 5 percent [...]
10
04, 2012
Types of GIST
Newly Diagnosed | Glossary | GIST Education | GIST FAQs | Pathology Report There are a number of types of GIST. Less than 20 years ago, GIST was a disease [...]
10
04, 2012
KIT/PDGFRa Mutant GIST
Newly Diagnosed | Glossary | GIST Education | GIST FAQs | Pathology Report Less than 20 years ago, GIST was a disease frequently misdiagnosed – usually as leiomyosarcoma . Today, we know there [...]
1
12, 2011
CTOS wrap-up: LRG among key presenters
By Jim Hughes, LRG Clinical Trials Coordinator, and Pete Knox, LRG Special Projects Coordinator The 2011 Connective Tissue Oncology Society (CTOS) conference was held in late October this year in Chicago. If the meeting had a GIST [...]
1
08, 2011
ASCO 2011 Overview
This year’s American Society of Clinical Oncology conference (ASCO), held in Chicago in June, produced a number of interesting and informative GIST-relevant presentations. Below is an overview and we will be posting the rest of the articles very soon.
1
06, 2011
State of the GIST Community Part 3: What do we know about mutational testing?
As of May 1, 2011, the LRG patient registry only received 377 reports of mutations out of 1,327 patients, which only represents 28 percent of the entire registry. Part of this may be related to the fact that mutational testing is not common practice at diagnosis.
1
06, 2011
Mutational Testing & Survival: Where We Stand
Only six percent of GIST patients in the United States take advantage of testing that could be used to individualize their treatment according to a new article in the Annals of Oncology. Dr. Peter Pisters of MD Anderson Cancer Center in Houston, Texas and his colleagues reported results of the GIST reGISTry, a Novartis Pharmaceuticals-supported registry of 882 GIST patients in the United States.
6
01, 2011
PDGFRA Mutations: It’s time to consider mutational status for resistant GIST patients
January 6th, 2011 - By Jerry Call, LRG Science CoordinatorThe first ever clinical trial specifically for the PDGFRA D842V mutation has been announced by Arog pharmaceuticals. The phase II trial is scheduled to open in [...]
27
11, 2010
Adjuvant Gleevec: To Take or Not to Take?
In presentations at the 2010 American Society of Clinical Oncologists conference (ASCO), Dr. Ronald DeMatteo, Memorial Sloan-Kettering Cancer Center (MSKCC) and Dr. Chris Corless, Oregon Health & Science University (OHSU), presented new data from the Z9001 adjuvant Gleevec trial. As Dr. DeMatteo noted, the presentations were geared towards answering two questions: Who should get adjuvant Gleevec and how long should they get it for? While the presentations went a long way towards answering who should get adjuvant Gleevec, there appears to be much that we do not know about how long they should get it for. Other ongoing trials may help shed more light on this question.
Need a new search?
If you didn't find what you were looking for, try a new search!